Objective: Epidermal growth factor receptor (EGFR) gene mutation status is a well-established predictor of the efficacy of EGFR tyrosine-kinase inhibitor (TKI) therapy in patients with non-small cell lung cancer. Recently, differences in EGFR mutation subtypes have been reported to be associated with the efficacy of EGFR-TKI therapy. The prognostic impact of EGFR mutation status and subtypes remains controversial, however.
Perspective
We have shown that positive EGFR mutation status is a favorable prognostic factor independent of TNM stage in patients with surgically resected lung adenocarcinomas. During the next revision of the TNM classification of lung cancer, cancer genotype might be adapted as a new category, and in future clinical trials for adjuvant therapy, stratification by EGFR mutation status might be necessary to avoid bias.
See Editorial Commentary page 1775.
See Editorial page 1766.
Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent driveroncogene alterations in non-small cell lung cancer (NSCLC). EGFR mutations are more frequently found in females, those who have never smoked, patients with adenocarcinoma, and individuals of East Asian descent. 1 The frequency of EGFR mutations in nonadenocarcinoma NSCLCs is quite low (<2%). 1 The EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, which specifically block the EGFR-dependent pathway, were initially approved as molecular-targeting drugs for their use in the treatment of NSCLC.
2 EGFR-mutated NSCLC has become a clinically relevant molecular subset, because patients with NSCLC harboring activating EGFR mutations (exon 21 L858R mutation or exon 19 deletions) benefit from EGFR-TKI treatment, unlike those with EGFR wild-type (WT) tumors. 3, 4 Both the presence of EGFR mutations and differences in EGFR mutation subtypes (exon 21 L858R mutation or exon 19 deletions) have been associated with the efficacy of EGFR-TKIs. A meta-analysis of 8 clinical trials and 5 retrospective studies using EGFR-TKIs for advanced EGFR-mutated NSCLCs identified exon 19 deletion as associated with longer progression-free survival compared with exon 21 L858R mutation. 5 Therefore, both EGFR mutation status and EGFR mutation subtype are considered significant predictors of the efficacy of EGFR-TKI therapy in NSCLC.
In contrast, the prognostic impact of both EGFR mutation status and EGFR subtype in patients with NSCLC remains controversial. A systematic review with a meta-analysis based on data from 16 studies (n ¼ 3337) showed that EGFR mutations were not a prognostic factor in patients with surgically resected NSCLC 6 ; however, all of the studies included in the meta-analysis were of a retrospective design, included only small numbers of patients, had a relatively short follow-up period, and involved heterogeneous treatments for recurrent disease (especially regarding the use of EGFR TKI). Therefore, as a matter of course, further study is needed to confirm the results. The prognostic impact of EGFR mutation subtypes (exon 21 L858R point mutation or exon 19 deletions) in patients with NSCLC has not been well established, given the paucity of studies investigating the prognostic impact of EGFR mutation subtypes in patients with early-stage NSCLC who underwent surgical resection. [7] [8] [9] In the present study, we explored the prognostic impacts of EGFR mutation status and EGFR subtype in patients with surgically resected lung adenocarcinomas.
METHODS Patients
Between January 2010 and December 2014, a total of 1018 patients with lung adenocarcinomas underwent complete surgical resection at Juntendo University School of Medicine (Tokyo, Japan). Among these patients, we retrospectively reviewed clinicopathological data for 939 consecutive patients with lung adenocarcinomas who had available data on EGFR mutation status. A flowchart illustrating the selection of the study cohorts is shown in Figure 1 .
Preoperative staging was routinely performed with computed tomography (CT) scans of the chest and upper abdomen and 18 F-fluoro-2-deoxy-glucose positron emission tomography (PET)/CT scans of the chest and upper abdomen. Cranial CT scanning or magnetic resonance imaging (MRI) was performed based on clinical signs and symptoms. The patients were staged based on the seventh edition of the International Association for the Study of Lung Cancer TNM classification for lung cancer. 10 No patient receive induction chemotherapy or radiotherapy, or treatments with EGFR-TKI as induction or adjuvant therapy.
Follow-up and Diagnosis of Recurrence
Follow-up examinations were performed every 3 or 4 months for the first 3 years and then every 6 months thereafter. Chest X-rays and biochemical examination of blood, including for carcinoembryonic antigen (CEA), were performed at each visit to the outpatient department. Chest CT or PET/CT scans were performed annually. Cranial CT scans and MRI were performed as necessary. Recurrence was diagnosed based on radiologic evidence of cancer relapse on surveillance imaging and/or pathological evidence according to tumor biopsy analysis.
EGFR Mutation Analysis
We routinely analyzed EGFR mutations for lung cancer patients who underwent surgery for a research purpose. Genomic DNA was extracted from cubes (3 to 5 mm 3 ) of frozen, fresh lung cancer tissue samples from surgically resected specimens. The peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method 11 was used to identify EGFR mutations G719A, G719C, and G719A in exon 18; all deletion genotypes in exon 19; T790M in exon 20; and L858R and L861Q in exon 21.
Approval for collection of patient specimens from the tissue bank in our department was obtained from the Institutional Review Board of Juntendo University School of Medicine (no. 2014172). Individual patient consent was obtained for the procurement of tissue for research purposes before surgery. This retrospective study was performed under a waiver of authorization approved by the Institutional Review Board. 
Statistical Analysis
Overall survival (OS) and recurrence-free survival (RFS) were analyzed by the Kaplan-Meier method, and curve differences were tested using the log-rank test according to pathological stage, EGFR mutation status, and EGFR mutation subtypes. The duration of OS was defined as the interval between the date of surgical intervention and the date of either death or the last follow-up. The duration of RFS was defined as the interval between the date of surgical intervention and the date of recurrence, death from any cause, or the last follow-up. Univariate and multivariate analyses of independent prognostic factors in each cohort were performed using the Cox proportional hazards model. All significant variables (P <.05) in the univariate analyses were entered into the multivariate analyses using a stepwise variable selection procedure to adjust for potential confounding factors.
A P value < .05 was considered to indicate statistical significance. All statistical analyses were performed using SPSS version 20.0 (IBM, Armonk, NY).
RESULTS
EGFR mutations were detected in 418 of the 939 patients with lung adenocarcinoma (45%), with the point mutation L858R in exon 21 detected in 222 of 418 (53%) EGFR-mutated tumors and exon 19 deletions detected in 161 of these tumors (39%). Other minor EGFR mutations were detected in 23 tumors (6%), including mutations of exon 18 G719A in 8, exon 18 G719S in 5, exon 18 G719C in 3, exon 21 L861Q in 7, and exon 20 T790M in 4. Double mutations were found in 12 tumors (3%), including exon 21 L858R and exon 20 T790M in 8 and exon 20 T790M and exon 19 deletion, exon 20 T790M and exon 18 G719A, exon 18 G719A and exon 21 L861Q, and exon 18 G719S and exon 21 L861Q in 1 each. Interestingly, exon 20 T790M, which confers resistance to EGFR-TKI, 12 was consistently coupled with other mutations. Patient characteristics are summarized in Table 1 . Female sex (P < .001), nonsmoker (P < .001), pathological stage I tumor (P ¼ .001), and tumor without vascular invasion (P ¼ .002) were more frequent in patients with EGFR-mutated tumors compared with patients with EGFR WT tumors.
To evaluate the prognostic impact of EGFR mutation status, we analyzed OS and RFS in 939 patients, with a median follow-up of 48 months. The 3-/5-year OS rates were 95% [95% confidence interval (CI), 92%-97%]/89% (95% CI, 84%-92%) in the 418 patients with EGFR-mutated tumors and 85% (95% CI, 82%-88%)/78% (95% CI, 73%-82%) in the 521 patients with EGFR WT tumors. Positive EGFR mutation status was significantly associated with longer OS in all patients (P < .001; Figure 2 , A). The 3-/5-year RFS rates were 85% (95% CI, 81%-88%)/81% (95% CI, 76%-85%) in the 418 patients with EGFR-mutated tumors and 78% (95% CI, 75%-82%)/72% (95% CI, 68%-77%) in the 521 patients with EGFR WT tumors, with positive EGFR mutation status significantly associated with longer RFS in all patients (P ¼ .002; Figure 2 , B).
The 3-/5-year OS rates were 98% (95% CI, 96%-99%)/ 94% (95% CI, 90%-97%) in the 350 patients with EGFR-mutated pathological stage I tumors and 93% (95% CI, 90%-95%)/87% (95% CI, 83%-91%) in the 391 patients with EGFR WT pathological stage I tumors. Positive EGFR mutation status was significantly associated with longer OS in patients in pathological stage I (P ¼ .003; Figure E1 , A). In addition, the 3-/5-year RFS rates were 93% (95% CI, 90%-96%)/89% (95% CI, 84%-93%) in the 350 patients with EGFR-mutated pathological stage I tumors and 90% (95% CI, 86%-93%)/84% (95% CI, 80%-88%) in the 391 patients with EGFR WT pathological stage I tumors. Here again, positive EGFR mutation status was associated with longer RFS in the patients with pathological stage I tumors; however, the difference was not statistically significant (P ¼ .065; Figure E1, B) . Cox regression analysis of prognostic factors for OS in all patients identified EGFR mutation status as a significant prognostic factor independent of well-established prognostic factors including age, serum CEA level, pathological stage, vascular invasion, and lymphatic permeation (Tables 2 and 3 ). Cox regression analysis of prognostic factors for RFS in all patients identified EGFR mutation status as a significant prognostic factor in the univariate analysis, but not in the multivariate analysis (Tables 2 and 3 ). To evaluate the prognostic impact of EGFR mutation subtypes, we analyzed OS and RFS rates for patients with EGFR-mutated tumors in 3 groups stratified by EGFR mutation subtypes: exon 19 deletions, L858R, and other subtypes, including minor mutations or double mutations. In 418 patients with EGFR-mutated tumors, we found no significant differences in OS and RFS rates according to mutation subtype ( Figure 3 Postoperative recurrences developed in 57 patients with EGFR-mutated tumors, including 10 locoregional only, 31 distant only, and 16 locoregional and distant. Among these 57 patients, 41 were treated with EGFR-TKIs following recurrence, and OS time tended to be longer in these patients compared with that in 16 patients not treated with EGFR-TKIs; however, the difference was not statistically significant (P ¼ .173; Figure 4 ). In the 41 patients who received EGFR-TKI treatment, both OS and survival Figure E2 ).
DISCUSSION
EGFR mutation status and subtype indisputably constitute significant predictive factors for the efficacy of EGFR-TKIs in advanced NSCLC; however, their prognostic role remains unclear, given the inconsistent results from previous studies of small and heterogeneous populations. [6] [7] [8] Elucidation of the intrinsic prognostic impact of EGFR mutation status and EGFR mutation subtypes in patients with advanced EGFR-mutated NSCLC is currently considered impossible, because EGFR-TKIs are used as standard first-line treatment.
Furthermore, third-generation EGFR-TKIs were recently shown to prolong survival, even after the development of resistance to first-or second-generation EGFR-TKIs. 13 Increasingly prolonged survival is expected for patients with advanced EGFR-mutated NSCLC. Even in the presence or absence of intrinsic prognostic impacts associated with EGFR mutation status and subtypes, their affect would be obscured by a definitive association with the efficacy of EGFR-TKIs. Therefore, the intrinsic prognostic roles of EGFR mutation status and subtype require investigation in patients with surgically resected early-stage NSCLC who did not receive perioperative therapy with EGFR-TKIs.
To the best of our knowledge, the present study is the largest-scale evaluation of patients with surgically resected EGFR-mutated tumors for evaluating the prognostic impact of EGFR mutation status and subtypes by analyzing both OS and RFS rates reported to date. We found that positive EGFR mutation status was significantly associated with longer OS regardless of pathological stage in Kaplan-Meier analyses. Furthermore, multivariate analysis identified EGFR mutation status as a significant prognostic factor for OS independent of pathological stage. In addition, although the number of patients who received EGFR-TKIs for postoperative recurrence was small, there was no statistical difference in OS between whether patients with recurrent EGFR-mutated tumors received or did not receive EGFR-TKI treatment. The duration of OS might not be significantly influenced by EGFR-TKI treatment for postoperative recurrence; thus, we conclude that positive EGFR mutation status is a favorable prognostic factor in patients with surgically resected lung adenocarcinomas. In contrast, we observed no significant differences in OS and RFS between patients with an exon 21 L858R mutation (n ¼ 222) and those with exon 19 deletions in EGFR-mutated tumors (n ¼ 161). In 41 patients who received EGFR-TKI treatment, both OS and survival following recurrence were longer in patients with tumors harboring exon 19 deletions (n ¼ 19) compared with those with tumors harboring an L858R mutation (n ¼ 18), although the differences were not statistically significant. Thus, we conclude that EGFR mutation subtype (exon 21 L858R mutation or exon 19 deletions) has no prognostic impact on patients with surgically resected lung adenocarcinomas. Larger-scale studies are needed to confirm these observations, however.
Although the underlying mechanism associated with the favorable prognostic impact of EGFR mutations in lung adenocarcinoma remains unclear, EGFR-mutated lung adenocarcinomas may be less likely to be affected by complex oncogenic processes, given that EGFR mutations provide strong growth advantages due to their constitutive activation. Therefore, EGFR-mutated lung adenocarcinoma cells need not acquire additional oncogenic mutations to enhance their biological malignancy via cell-based characteristics, such as invasive, antiapoptotic, and metastatic potentials. As a result, EGFR-mutated lung adenocarcinomas (non-smoking-related lung cancer) may acquire a lower degree of biological malignancy relative to that observed in smoking-related lung cancers exhibiting a high nonsynonymous mutation burden.
14 TNM classifications for lung cancer were recently revised by the International Association for the Study of Lung Cancer's Staging Committee. 15 Although the revised TNM staging system adapted categories based on prognostic factors associated with the anatomic extent of tumors, no consideration was given to the biological features of tumors, such as driver mutations. Recent advances in the understanding of NSCLC-related molecular biology likely will offer the potential for therapeutic success by matching systemic target therapies to cancer genotype. EGFR mutations offer not only predictive significance for EGFR-TKI treatment, but also improved prognostic significance from a biological standpoint for lung adenocarcinomas. Other alterations in driver oncogenes with a prognostic impact similar to that of EGFR mutations might be identified in the future. Therefore, regardless of how precise the classification system becomes, a TNM staging system based solely on the anatomic extent of tumors will become outdated and virtually irrelevant to clinical practice in the era of molecular-target therapy. In the next revision to the TNM classification of lung cancer, cancer genotype might be adapted as a new category.
Several clinical trials have reported higher chemotherapy response rates in the presence of EGFR mutations in both first-line and second-line advanced NSCLC settings. 16, 17 In phase III studies of adjuvant gefitinib (BR19) and erlotinib (RADIANT) for patients with completely resected stage IB to IIIA NSCLCs, EGFR-TKI therapy failed to show a survival benefit compared with placebo in subgroups of patients with EGFR-mutated tumors. 18, 19 However, in their retrospective study D'Angelo and colleagues 20 reported that adjuvant therapy with gefitinib or erlotinib was significantly associated with a lower risk of recurrence or death, disease-free survival, and a trend toward improved OS. In a randomized phase II study, adjuvant therapy with gefitinib following pemetrexed and carboplatin showed significantly improved disease-free survival in patients with stage IIIA NSCLC harboring EGFR mutations compared with pemetrexed and carboplatin treatment alone. 21 However, in disagreement with our results, positive EGFR mutation status was recently identified as a favorable independent prognostic factor for survival periods following recurrence. 22 Therefore, stratification by EGFR mutation status might be necessary to avoid an uneven distribution of EGFR mutant populations that could potentially confound survival data in future clinical trials related to adjuvant therapy.
Our study must be interpreted in the context of several limitations. First, although the number of the EGFR mutant cohort was the largest evaluated to date, this study represents a retrospective comparative study at a single institution, and thus patient selection bias is inevitable. Second, the intrinsic prognostic role of EGFR mutation (ie, EGFR mutation as a prognostic factor) might not have been accurately evaluated, given that we could not completely exclude the efficacy of EGFR-TKI treatment (ie, EGFR mutation as a predictive factor); that is, our study did not include any patients who received EGFR-TKI treatment in the induction or adjuvant setting. Nevertheless, 41 of 939 patients (4%) received EGFR-TKI treatment for postoperative recurrences. Third, although EGFR-TKI treatment for patients with recurrent EGFR-mutated tumors was not associated with a statistically significant increase in OS, the number of patients who received EGFR-TKI treatment for postoperative recurrence might be too small to allow for a definitive conclusion. Larger-scale studies in this population are warranted.
In conclusion, our analyses indicate that positive EGFR mutation status is a favorable prognostic factor in patients with surgically resected lung adenocarcinomas. Our results also show that EGFR mutation subtype (L858R mutation or exon19 deletions) has no prognostic impact, although it might be a significant predictor of EGFR-TKI efficacy (Video 1).
